
The zzso community usually perceives phase I zzso trials as associated with poor or limited benefits and substantial zzso There is scarce data concerning outcome and survival of patients enrolled in current phase I zzso zzso 

We reviewed all phase I zzso trials conducted by investigators from the Adult Phase I Unit at Institut Gustave zzso from 2003 to zzso We report data concerning patient zzso treatment outcome, zzso survival and type of care after trial zzso 

We analyzed 10 trials involving 180 zzso The overall response rate was zzso Disease control zzso response plus stable disease) was achieved in zzso of zzso The rate of toxic death was zzso In all, 38% of patients had at least one episode of grade 3 or 4 toxic zzso The median zzso survival and the median overall survival zzso were zzso and zzso months, zzso On zzso analysis, a time between diagnosis of disease and inclusion in the phase I trial zzso or zzso months and evidence of disease control were statistically significant zzso of improved zzso 

Current phase I zzso trials are safe and are associated with clinical benefit in a substantial proportion of zzso 

